Source: Annual Congress 2012 - Cystic fibrosis (adults and children): risk factors and clinical problems
Disease area: Paediatric lung diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
R. Beri, R. Jassal, D. Shah, W. Bashari, S. Whewall, A. Norcup, A.Y.H. Lim (Stoke-on-Trent, United Kingdom). The prevalence and characteristics of intravenous (IV) antibiotics allergy in adult patient with cystic fibrosis (CF). Eur Respir J 2012; 40: Suppl. 56, 1120

Member's Comments

No comment yet.

Related content which might interest you: Safety and efficacy of intravenous (IV) Fosfomycin in adult cystic fibrosis patients Source: International Congress 2018 – Latest developments in cystic fibrosis Year: 2018 The oral AntibioticS approprIateness score (OASIS) – A novel scoring system to assess antibiotic route in pulmonary exacerbations of cystic fibrosis (CF) Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013 Longitudinal performance of the bronchiectasis severity index (BSI) in patients on regular intravenous (IV) antibiotic therapy for bronchiectasis Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections Year: 2016 Pseudomonas aeruginosa (Pa) antibiotic resistance (AR): Comparison in adults and children with cystic fibrosis (CF) Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more Year: 2010 Macrolides in cystic fibrosis (CF); clinical experience Source: Eur Respir J 2004; 24: Suppl. 48, 615s Year: 2004 Nebulised antibiotics with the I-neb adaptive aerosol delivery (AAD) system: Impact on adherence in cystic fibrosis (CF) patients Source: Annual Congress 2012 - Cystic fibrosis (adults and children): risk factors and clinical problems Year: 2012 High frequency chest wall oscillation (HFCWO) in the treatment of acute pulmonary exacerbation in adult cystic fibrosis (CF) patients Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children Year: 2013 The impact of Achromobacter xylosoxidans on lung function and hospital admissions in adult patients with cystic fibrosis (CF) Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease Year: 2009 Ventilation inhomogeneity (VI) and spirometry in response to intravenous antibiotics (IVab) in cystic fibrosis (CF) Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children Year: 2013 The pharmacokinetic of the main oral antibiotics in children with cystic fibrosis. Source: International Congress 2019 – Treatments, adherence and psychosocial aspects of cystic fibrosis Year: 2019 Relationship between nasal potential difference (NPD) and respiratory function in cystic fibrosis (CF) patients Source: Eur Respir J 2001; 18: Suppl. 33, 125s Year: 2001 Usefulness of long term treatment with azithromycin in patients with bronchiectasis (non cystic fibrosis) Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010 Diagnostic and therapeutic difficulties in pulmonary aspergillosis (PA) in paediatric cystic fibrosis (CF) patients Source: Eur Respir J 2006; 28: Suppl. 50, 485s Year: 2006 Home intravenous antibiotic treatments in cystic fibrosis adult patients Source: Eur Respir J 2002; 20: Suppl. 38, 158s Year: 2002 The effect of transition from a paediatric to adult cystic fibrosis (CF) centre on clinical status and hospital attendance Source: International Congress 2016 – From pleura to bronchi: new insights Year: 2016 Magnetic-resonance-imaging (MRI) for assessment of regional therapy response in patients with cystic fibrosis (CF) Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease Year: 2009 A UK experience of temocillin in the treatment of adult cystic fibrosis patients Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools Year: 2008 Prevalence of renal impairment in an adult cystic fibrosis (CF) centre Source: Eur Respir J 2005; 26: Suppl. 49, 622s Year: 2005 Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non-cystic fibrosis (CF) bronchiectasis (BE) Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis Year: 2011 Hyperinflation in adult cystic fibrosis (CF) patients: Clinical and functional correlates Source: Annual Congress 2010 - Cystic fibrosis: clinical and laboratory studies Year: 2010